Please login to the form below

Not currently logged in

Merck/ Parexel biosimilar alliance

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates.

The agreement will see Parexel, a contract research organisation (CRO) with a focus on the biopharma industry, provide Merck  with access to global clinical development services for designated biosimilar candidates. The biosimilar candidates span several therapy areas.

A dedicated unit of Merck BioVentures,  the division of Merck focused on the development of biosimilars, will also be established within Parexel.

Financial details of the deal were not disclosed.

"Through this agreement, Merck BioVentures has secured broad strategic access to Parexel's proven biosimilar clinical development experience," said Michael Kamarck, president , Merck BioVentures. "This agreement positions Merck BioVentures for success with an industry leading partner that has the expertise and resources to conduct clinical development of our diverse portfolio of candidates to allow timely delivery of products to the marketplace."

Josef von Rickenbach, chairman and CEO of Parexel, was also positive about the agreement: "We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide."

13th January 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...